William Cohen, DO
Otolaryngology/Facial Plastic Surgery · Orange, CANPI 1073545968
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Intersect ENT, Inc. at 24.9% of the total. Reporting peaked in 2019 at $370 and has fallen 66.1% since, to $126 in 2025.
Across 46 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$298
- GSK$235
- Aerin Medical Inc.$130
- Stryker$109
- Optinose US, Inc.$101
- Cook Medical LLC$86
- plus $239 from 6 others
What the payments were for
- Food & beverage$1,198100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 7 | $298 |
| GSK | 12 | $235 |
| Aerin Medical Inc. | 5 | $130 |
| Stryker | 2 | $109 |
| Optinose US, Inc. | 5 | $101 |
| Cook Medical LLC | 2 | $86 |
| Smith+Nephew | 3 | $69 |
| Integra Lifesciences Corporation | 2 | $50 |
| Medtronic | 2 | $46 |
| Galderma Laboratories, L.p. | 3 | $43 |
| Acclarent, Inc | 2 | $27 |
| Apyx Medical Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROPEL$131
How this compares
$1,198 in reported general payments places this provider in the 55th percentile of 102 otolaryngology/facial plastic surgery providers in California.
See all otolaryngology/facial plastic surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 12 | $90,270 |
| Azelastine Hcl | 224 | $4,356 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 38 | $3,518 |
| Fluticasone Propionate | 263 | $3,442 |
| Ipratropium Bromide | 67 | $2,106 |
| Omeprazole | 198 | $1,648 |
| Fluocinolone Acetonide Oil | 40 | $1,207 |
| Famotidine | 24 | $256 |
| Pantoprazole Sodium | 29 | $249 |
| Methylprednisolone | 42 | $227 |
| Levothyroxine Sodium | 18 | $201 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $176 |
| Cephalexin | 37 | $172 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $70 |
| Tramadol Hcl | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala | $235 | $90,27012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 102 otolaryngology/facial plastic surgery providers in California.
Other otolaryngology/facial plastic surgery in Orange
- Sarmela SunderLancaster$85K
- Vasu DiviStanford$51K
- Jen ChowArcadia$26K
- Ryan CasserlyMonterey$23K
- Ritvik MehtaCarlsbad$13K
- Alexis FurzeNewport Beach$12K
- Jahangir SharifiLos Angeles$12K
- Henry NguyenRancho Cucamonga$11K
- Paul NassifBeverly Hills$10K
- Babak AzizzadehBeverly Hills$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.